Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. - Full Text View - Clinica
Links shared publicly online about this topic.
- 1,472total visits
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. - Full Text View - Clinica
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. - Full Text View - ClinicalTrials.gov
View full resource at clinicaltrials.gov
Tags: Cancer, Chemotherapy, Lymphoma, Hodgkin Lymphoma, Stem Cell, Mayo Clinic, Transplantation
Most Recently Shared on January 8, 2010 at 3:46 am By:
Trial for refractory Hodgkin Lymphoma pts at Mayo Clinic. http://bit.ly/4MRM8A
Advertisement
